AKSHAY S THOMAS
- Type
- Physician · Allopathic & Osteopathic Physicians / General Practice
- Where
- BOWLING GREEN, KY
- NPI
- 1528324662
- Received
- $108,370 in 222 records, 2019 to 2025
- As principal investigator
- $698,819 of research payments to others in 66 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 36 | $10,179 |
| 2024 | General payment | 49 | $20,171 |
| 2023 | General payment | 36 | $19,805 |
| 2022 | General payment | 37 | $25,588 |
| 2021 | General payment | 27 | $18,262 |
| 2020 | General payment | 17 | $8,598 |
| 2019 | General payment | 20 | $5,765 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Genentech USA, Inc. | 51 | $46,494 | 2019–2025 |
| Carl Zeiss Meditec, Inc. | 5 | $11,524 | 2020–2021 |
| Alimera Sciences, Inc. | 19 | $10,941 | 2019–2024 |
| Bausch & Lomb Americas Inc. | 9 | $7,918 | 2022–2025 |
| Allergan, Inc. | 14 | $6,890 | 2019–2021 |
| EyePoint Pharmaceuticals US, Inc. | 19 | $5,830 | 2020–2024 |
| Bausch & Lomb, a division of Bausch Health US, LLC | 7 | $5,360 | 2019–2020 |
| Novartis Pharmaceuticals Corporation | 9 | $5,073 | 2019–2022 |
| Regeneron Pharmaceuticals, Inc. | 7 | $2,982 | 2019–2025 |
| ANI Pharmaceuticals, Inc. | 4 | $2,090 | 2025 |
| ABBVIE INC. | 12 | $963 | 2022–2025 |
| Regeneron Healthcare Solutions, Inc. | 15 | $442 | 2019–2025 |
| Astellas Pharma US Inc | 13 | $425 | 2023–2025 |
| Apellis Pharmaceuticals, Inc. | 17 | $410 | 2022–2025 |
| Biogen, Inc. | 8 | $265 | 2022–2024 |
| Dutch Ophthalmic, USA | 2 | $166 | 2024 |
| Coherus Oncology, Inc. | 2 | $159 | 2022–2023 |
| Neurotech Pharmaceuticals, Inc. | 1 | $125 | 2025 |
| Ocular Therapeutix, Inc. | 2 | $121 | 2024–2025 |
| Genentech, Inc. | 2 | $89 | 2024 |
| Harrow Eye, LLC | 2 | $60 | 2025 |
| Mallinckrodt Enterprises LLC | 1 | $17 | 2019 |
| Amgen Inc. | 1 | $15 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 24 | $54,065 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 7 | $28,920 |
| Honoraria | 6 | $10,287 |
| Food and Beverage | 168 | $8,013 |
| Travel and Lodging | 16 | $7,077 |
| Education | 1 | $6 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-11-20 | ANI Pharmaceuticals, Inc. | $2,025 | Honoraria | Cash or cash equivalent | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | 2025 | |
| 2025-11-20 | Astellas Pharma US Inc | $31 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-11-19 | Astellas Pharma US Inc | $23 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-11-12 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2025 | |
| 2025-11-07 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2025 | |
| 2025-10-17 | Bausch & Lomb Americas Inc. | $149 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-16 | Apellis Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2025 | |
| 2025-10-16 | Astellas Pharma US Inc | $21 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-09-23 | Apellis Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2025 | |
| 2025-08-26 | Astellas Pharma US Inc | $31 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-08-25 | Ocular Therapeutix, Inc. | $21 | Food and Beverage | In-kind items and services | DEXTENZA Drug, Corticosteroid intracanalicular insert | 2025 | |
| 2025-08-16 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2025 | |
| 2025-07-31 | Harrow Eye, LLC | $32 | Food and Beverage | In-kind items and services | TRIESENCE Drug, OPTOMETRY | 2025 | |
| 2025-07-22 | Apellis Pharmaceuticals, Inc. | $30 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2025 | |
| 2025-07-22 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2025 | |
| 2025-07-21 | ANI Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | 2025 | |
| 2025-06-13 | Regeneron Pharmaceuticals, Inc. | $1,880 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-13 | Regeneron Pharmaceuticals, Inc. | $705 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-13 | Regeneron Pharmaceuticals, Inc. | $235 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-10 | Bausch & Lomb Americas Inc. | $4,250 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-10 | Genentech USA, Inc. | $122 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2025 | |
| 2025-06-10 | Apellis Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2025 | |
| 2025-06-02 | Neurotech Pharmaceuticals, Inc. | $125 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-27 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2025 | |
| 2025-05-20 | Astellas Pharma US Inc | $29 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-05-01 | ANI Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | 2025 | |
| 2025-04-15 | Apellis Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2025 | |
| 2025-04-14 | Astellas Pharma US Inc | $25 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-04-03 | Harrow Eye, LLC | $28 | Food and Beverage | In-kind items and services | IHEEZO Drug, OPTOMETRY | 2025 | |
| 2025-03-25 | Astellas Pharma US Inc | $24 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-02-20 | Apellis Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2025 | |
| 2025-02-06 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | PAVBLU Biological, Inflammation | 2025 | |
| 2025-02-03 | ANI Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-01-28 | Apellis Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2025 | |
| 2025-01-09 | Astellas Pharma US Inc | $24 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-01-07 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2025 | |
| 2024-12-19 | Alimera Sciences, Inc. | $1,062 | Honoraria | Cash or cash equivalent | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | 2024 | |
| 2024-12-19 | Apellis Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2024 | |
| 2024-11-29 | Genentech USA, Inc. | $1,339 | Travel and Lodging | Cash or cash equivalent | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-11-21 | Genentech USA, Inc. | $5,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-11-14 | Dutch Ophthalmic, USA | $140 | Food and Beverage | In-kind items and services | EVA, combined machine Device, Ophthalmology | 2024 | |
| 2024-11-12 | Apellis Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2024 | |
| 2024-11-10 | Genentech, Inc. | $66 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-11-06 | Alimera Sciences, Inc. | $22 | Food and Beverage | In-kind items and services | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | 2024 | |
| 2024-11-02 | Genentech USA, Inc. | $5,755 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-02 | Genentech USA, Inc. | $343 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-11-02 | Genentech USA, Inc. | $267 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-11-02 | Genentech USA, Inc. | $129 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-02 | Genentech USA, Inc. | $85 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-02 | Genentech USA, Inc. | $83 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-11-02 | Genentech USA, Inc. | $74 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-30 | Genentech, Inc. | $22 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-10-29 | Astellas Pharma US Inc | $23 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2024 | |
| 2024-10-20 | EyePoint Pharmaceuticals US, Inc. | $1,387 | Consulting Fee | Cash or cash equivalent | EYP-1901 Drug, Wet Age Related Macular Degeneration (wAMD) | 2024 | |
| 2024-10-20 | EyePoint Pharmaceuticals US, Inc. | $184 | Food and Beverage | In-kind items and services | EYP-1901 Drug, Wet Age Related Macular Degeneration (wAMD) | 2024 | |
| 2024-10-20 | Ocular Therapeutix, Inc. | $99 | Food and Beverage | In-kind items and services | DEXTENZA Drug, Corticosteroid intracanalicular insert | 2024 | |
| 2024-10-18 | Bausch & Lomb Americas Inc. | $147 | Food and Beverage | In-kind items and services | XIPERE Drug, Ophthalmology | 2024 | |
| 2024-10-16 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2024 | |
| 2024-10-16 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2024 | |
| 2024-10-03 | Genentech USA, Inc. | $125 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-09-30 | Genentech USA, Inc. | $30 | Food and Beverage | In-kind items and services | Susvimo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-09-04 | EyePoint Pharmaceuticals US, Inc. | $11 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-22 | Dutch Ophthalmic, USA | $26 | Food and Beverage | In-kind items and services | EVA, combined machine Device, Ophthalmology | 2024 | |
| 2024-08-21 | Genentech USA, Inc. | $32 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-08-06 | Alimera Sciences, Inc. | $120 | Food and Beverage | In-kind items and services | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | 2024 | |
| 2024-07-31 | Apellis Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2024 | |
| 2024-07-12 | Bausch & Lomb Americas Inc. | $137 | Food and Beverage | In-kind items and services | Stellaris Device, Ophthalmology | 2024 | |
| 2024-06-20 | Genentech USA, Inc. | $2,115 | Consulting Fee | Cash or cash equivalent | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-06-19 | Alimera Sciences, Inc. | $11 | Food and Beverage | In-kind items and services | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | 2024 | |
| 2024-06-17 | Apellis Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2024 | |
| 2024-05-28 | Genentech USA, Inc. | $115 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-05-22 | Biogen, Inc. | $20 | Food and Beverage | In-kind items and services | BYOOVIZ Biological, Ophthalmology | 2024 | |
| 2024-05-16 | Astellas Pharma US Inc | $28 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2024 | |
| 2024-05-01 | Astellas Pharma US Inc | $100 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2024 | |
| 2024-04-29 | Astellas Pharma US Inc | $26 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2024 | |
| 2024-04-21 | Biogen, Inc. | $23 | Food and Beverage | In-kind items and services | BYOOVIZ Biological, Ophthalmology | 2024 | |
| 2024-04-15 | Apellis Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2024 | |
| 2024-04-05 | EyePoint Pharmaceuticals US, Inc. | $37 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-03-29 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2024 | |
| 2024-03-21 | Biogen, Inc. | $28 | Food and Beverage | In-kind items and services | BYOOVIZ Biological, Ophthalmology | 2024 | |
| 2024-03-07 | Genentech USA, Inc. | $33 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-03-07 | Genentech USA, Inc. | $3 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2024 | |
| 2024-02-20 | Apellis Pharmaceuticals, Inc. | $25 | Food and Beverage | In-kind items and services | Syfovre Drug, Ophthalmology | 2024 | |
| 2024-02-14 | Biogen, Inc. | $25 | Food and Beverage | In-kind items and services | BYOOVIZ Biological, Ophthalmology | 2024 | |
| 2024-01-11 | EyePoint Pharmaceuticals US, Inc. | $22 | Food and Beverage | In-kind items and services | 2024 | ||
| 2023-12-01 | Bausch & Lomb Americas Inc. | $95 | Food and Beverage | In-kind items and services | XIPERE Drug, Ophthalmology | 2023 | |
| 2023-11-29 | Alimera Sciences, Inc. | $18 | Food and Beverage | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2023 | |
| 2023-11-21 | EyePoint Pharmaceuticals US, Inc. | $694 | Consulting Fee | Cash or cash equivalent | EYP-1901 | 2023 | |
| 2023-11-05 | EyePoint Pharmaceuticals US, Inc. | $1,387 | Consulting Fee | Cash or cash equivalent | EYP-1901 | 2023 | |
| 2023-11-05 | EyePoint Pharmaceuticals US, Inc. | $152 | Food and Beverage | In-kind items and services | EYP-1901 | 2023 | |
| 2023-10-18 | Genentech USA, Inc. | $3 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-10-11 | Genentech USA, Inc. | $33 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-09-29 | Apellis Pharmaceuticals, Inc. | $21 | Food and Beverage | Cash or cash equivalent | Syfovre Drug, Ophthalmology | 2023 | |
| 2023-08-18 | Apellis Pharmaceuticals, Inc. | $19 | Food and Beverage | Cash or cash equivalent | Syfovre Drug, Ophthalmology | 2023 | |
| 2023-08-17 | Biogen, Inc. | $28 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-08-15 | Bausch & Lomb Americas Inc. | $618 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-09 | Astellas Pharma US Inc | $31 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-18 | Bausch & Lomb Americas Inc. | $2,475 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-07-18 | Regeneron Healthcare Solutions, Inc. | $17 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2023 | |
| 2023-06-27 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2023 | |
| 2023-06-11 | Genentech USA, Inc. | $5,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-06-11 | Genentech USA, Inc. | $414 | Travel and Lodging | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-06-11 | Genentech USA, Inc. | $189 | Travel and Lodging | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-06-11 | Genentech USA, Inc. | $85 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-06-06 | Genentech USA, Inc. | $137 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-06-01 | Alimera Sciences, Inc. | $24 | Food and Beverage | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2023 | |
| 2023-05-25 | Genentech USA, Inc. | $5,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-05-25 | Genentech USA, Inc. | $1,018 | Travel and Lodging | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-05-25 | Genentech USA, Inc. | $121 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-05-13 | Genentech USA, Inc. | $32 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-05-10 | EyePoint Pharmaceuticals US, Inc. | $35 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2023 | |
| 2023-04-28 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-04-22 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2023 | |
| 2023-03-30 | Apellis Pharmaceuticals, Inc. | $24 | Food and Beverage | Cash or cash equivalent | Syfovre Drug, Ophthalmology | 2023 | |
| 2023-03-09 | Genentech USA, Inc. | $660 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-03-09 | EyePoint Pharmaceuticals US, Inc. | $17 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2023 | |
| 2023-02-28 | Biogen, Inc. | $22 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-02-25 | Coherus Oncology, Inc. | $24 | Food and Beverage | In-kind items and services | Cimerli Biological, Ophthalmology | 2023 | |
| 2023-01-30 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2023 | |
| 2023-01-24 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | OZURDEX Drug, EYE CARE | 2023 | |
| 2023-01-19 | Biogen, Inc. | $21 | Food and Beverage | In-kind items and services | 2023 | ||
| 2022-12-19 | Bausch & Lomb Americas Inc. | $19 | Food and Beverage | In-kind items and services | XIPERE Drug, Ophthalmology | 2022 | |
| 2022-12-12 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-11-28 | Biogen, Inc. | $95 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-11-23 | EyePoint Pharmaceuticals US, Inc. | $326 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2022 | |
| 2022-11-23 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2022 | |
| 2022-11-15 | Coherus Oncology, Inc. | $134 | Food and Beverage | In-kind items and services | Cimerli Biological, Ophthalmology | 2022 | |
| 2022-11-09 | Genentech USA, Inc. | $5,280 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-11-09 | Genentech USA, Inc. | $122 | Food and Beverage | In-kind items and services | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-11-09 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-11-07 | Apellis Pharmaceuticals, Inc. | $17 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-10-31 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2022 | |
| 2022-10-10 | ABBVIE INC. | $775 | Consulting Fee | Cash or cash equivalent | OZURDEX Drug, RETINA | 2022 | |
| 2022-10-10 | EyePoint Pharmaceuticals US, Inc. | $19 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2022 | |
| 2022-10-05 | Genentech USA, Inc. | $5,280 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-10-05 | Genentech USA, Inc. | $100 | Food and Beverage | In-kind items and services | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-10-02 | Alimera Sciences, Inc. | $84 | Food and Beverage | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-10-02 | Regeneron Pharmaceuticals, Inc. | $54 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2022 | |
| 2022-09-27 | Alimera Sciences, Inc. | $1,200 | Honoraria | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-09-22 | Genentech USA, Inc. | $25 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2022 | |
| 2022-09-09 | Genentech USA, Inc. | $17 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2022 | |
| 2022-08-20 | Alimera Sciences, Inc. | $306 | Travel and Lodging | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-08-20 | Alimera Sciences, Inc. | $53 | Food and Beverage | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-08-16 | Alimera Sciences, Inc. | $2,500 | Honoraria | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-08-16 | Alimera Sciences, Inc. | $750 | Travel and Lodging | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-08-05 | EyePoint Pharmaceuticals US, Inc. | $1,417 | Consulting Fee | Cash or cash equivalent | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2022 | |
| 2022-07-15 | EyePoint Pharmaceuticals US, Inc. | $45 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2022 | |
| 2022-07-14 | ABBVIE INC. | $5 | Food and Beverage | Cash or cash equivalent | OZURDEX Drug, RETINA | 2022 | |
| 2022-07-12 | ABBVIE INC. | $6 | Education | In-kind items and services | OZURDEX Drug, RETINA | 2022 | |
| 2022-06-11 | Alimera Sciences, Inc. | $271 | Travel and Lodging | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-06-11 | Alimera Sciences, Inc. | $94 | Food and Beverage | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-06-07 | Alimera Sciences, Inc. | $2,500 | Honoraria | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-06-07 | Alimera Sciences, Inc. | $750 | Travel and Lodging | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-04-27 | Bausch & Lomb Americas Inc. | $23 | Food and Beverage | In-kind items and services | XIPERE Drug, Ophthalmology | 2022 | |
| 2022-04-20 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2022 | |
| 2022-04-17 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2022 | |
| 2022-03-08 | Novartis Pharmaceuticals Corporation | $2,400 | Consulting Fee | Cash or cash equivalent | BEOVU Drug, OPHTHALMOLOGY | 2022 | |
| 2022-02-08 | Genentech USA, Inc. | $780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VABYSMO Drug, Immunology and Ophthalmology | 2022 | |
| 2021-11-14 | Regeneron Pharmaceuticals, Inc. | $80 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2021 | |
| 2021-11-14 | EyePoint Pharmaceuticals US, Inc. | $17 | Food and Beverage | In-kind items and services | DEXYCU Drug, Postoperative Inflammation | 2021 | |
| 2021-11-13 | Genentech USA, Inc. | $126 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2021 | |
| 2021-11-02 | Novartis Pharmaceuticals Corporation | $94 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2021 | |
| 2021-10-10 | Allergan, Inc. | $55 | Food and Beverage | Cash or cash equivalent | OZURDEX Drug, RETINA | 2021 | |
| 2021-10-09 | Regeneron Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2021 | |
| 2021-10-08 | Allergan, Inc. | $55 | Food and Beverage | Cash or cash equivalent | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-30 | Allergan, Inc. | $4,655 | Consulting Fee | Cash or cash equivalent | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-30 | Allergan, Inc. | $542 | Travel and Lodging | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-30 | Allergan, Inc. | $198 | Travel and Lodging | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-30 | Allergan, Inc. | $193 | Travel and Lodging | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-30 | Allergan, Inc. | $135 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-30 | Allergan, Inc. | $83 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-30 | Allergan, Inc. | $63 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-30 | Allergan, Inc. | $59 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-30 | Allergan, Inc. | $57 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-30 | Allergan, Inc. | $19 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2021 | |
| 2021-07-27 | Genentech USA, Inc. | $14 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2021 | |
| 2021-07-13 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2021 | |
| 2021-07-01 | Regeneron Healthcare Solutions, Inc. | $15 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2021 | |
| 2021-05-12 | Genentech USA, Inc. | $147 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2021 | |
| 2021-04-29 | Novartis Pharmaceuticals Corporation | $2,400 | Consulting Fee | Cash or cash equivalent | BEOVU Drug, OPHTHALMOLOGY | 2021 | |
| 2021-04-21 | EyePoint Pharmaceuticals US, Inc. | $27 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2021 | |
| 2021-03-09 | Allergan, Inc. | $665 | Consulting Fee | Cash or cash equivalent | OZURDEX Drug, RETINA | 2021 | |
| 2021-03-04 | Carl Zeiss Meditec, Inc. | $4,250 | Consulting Fee | Cash or cash equivalent | CLARUS 700 Device, Fundus Camera | 2021 | |
| 2021-03-04 | Carl Zeiss Meditec, Inc. | $4,250 | Consulting Fee | Cash or cash equivalent | CLARUS 700 Device, Fundus Camera | 2021 | |
| 2021-01-15 | EyePoint Pharmaceuticals US, Inc. | $16 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2021 | |
| 2020-11-25 | Bausch & Lomb, a division of Bausch Health US, LLC | $17 | Food and Beverage | In-kind items and services | VISUDYNE Drug, OPHTHALMOLOGY | 2020 | |
| 2020-10-28 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2020 | |
| 2020-09-30 | EyePoint Pharmaceuticals US, Inc. | $14 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2020 | |
| 2020-09-02 | Bausch & Lomb, a division of Bausch Health US, LLC | $4,500 | Consulting Fee | Cash or cash equivalent | RETISERT Drug, OPHTHALMOLOGY | 2020 | |
| 2020-08-18 | EyePoint Pharmaceuticals US, Inc. | $15 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2020 | |
| 2020-07-17 | Novartis Pharmaceuticals Corporation | $11 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2020 | |
| 2020-07-02 | Carl Zeiss Meditec, Inc. | $300 | Consulting Fee | Cash or cash equivalent | CLARUS Device, Fundus Camera | 2020 | |
| 2020-06-09 | Novartis Pharmaceuticals Corporation | $11 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2020 | |
| 2020-03-04 | Bausch & Lomb, a division of Bausch Health US, LLC | $21 | Food and Beverage | In-kind items and services | VISUDYNE Drug, OPHTHALMOLOGY | 2020 | |
| 2020-02-18 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2020 | |
| 2020-02-12 | Genentech USA, Inc. | $129 | Food and Beverage | In-kind items and services | Lucentis Biological, Ophthalmology | 2020 | |
| 2020-02-03 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | BEOVU Drug, OPHTHALMOLOGY | 2020 | |
| 2020-01-31 | Regeneron Healthcare Solutions, Inc. | $27 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2020 | |
| 2020-01-20 | Bausch & Lomb, a division of Bausch Health US, LLC | $750 | Consulting Fee | Cash or cash equivalent | RETISERT Drug, OPHTHALMOLOGY | 2020 | |
| 2020-01-15 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2020 |
The latest 200 records of 222.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-10 | Genentech, Inc. | TENNESSEE RETINA PC | $8,552 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-11-03 | Genentech, Inc. | TENNESSEE RETINA PC | $27,258 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-10-27 | Genentech, Inc. | TENNESSEE RETINA PC | $2,420 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-10-13 | ANI Pharmaceuticals, Inc. | TENNESSEE RETINA PC | $1,210 | The SYNCHRONICITY Study | 2025 |
| 2025-09-02 | Genentech, Inc. | TENNESSEE RETINA PC | $6,744 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-08-15 | Genentech, Inc. | TENNESSEE RETINA PC | $16,925 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-08-11 | ANI Pharmaceuticals, Inc. | TENNESSEE RETINA PC | $9,982 | The SYNCHRONICITY Study | 2025 |
| 2025-08-11 | ANI Pharmaceuticals, Inc. | TENNESSEE RETINA PC | $2,056 | The SYNCHRONICITY Study | 2025 |
| 2025-08-11 | ANI Pharmaceuticals, Inc. | TENNESSEE RETINA PC | $3,631 | The SYNCHRONICITY Study | 2025 |
| 2025-07-17 | ANI Pharmaceuticals, Inc. | TENNESSEE RETINA PC | $1,210 | The SYNCHRONICITY Study | 2025 |
| 2025-07-08 | Genentech, Inc. | TENNESSEE RETINA PC | $1,702 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-07-03 | ANI Pharmaceuticals, Inc. | TENNESSEE RETINA PC | $1,210 | The SYNCHRONICITY Study | 2025 |
| 2025-06-18 | Genentech, Inc. | TENNESSEE RETINA PC | $11,097 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-06-09 | Genentech, Inc. | TENNESSEE RETINA PC | $350 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-06-06 | ANI Pharmaceuticals, Inc. | TENNESSEE RETINA PC | $4,659 | The SYNCHRONICITY Study | 2025 |
| 2025-05-20 | Genentech, Inc. | TENNESSEE RETINA PC | $5,897 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-05-14 | Genentech, Inc. | TENNESSEE RETINA PC | $1,373 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-05-13 | Genentech, Inc. | TENNESSEE RETINA PC | $12 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-04-16 | Genentech, Inc. | TENNESSEE RETINA PC | $1,702 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-03-20 | Genentech, Inc. | TENNESSEE RETINA PC | $17,659 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-03-20 | Genentech, Inc. | TENNESSEE RETINA PC | $1,373 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-03-20 | Genentech, Inc. | TENNESSEE RETINA PC | $2,746 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-03-20 | Genentech, Inc. | TENNESSEE RETINA PC | $1,373 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-03-20 | Genentech, Inc. | TENNESSEE RETINA PC | $17,992 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-03-20 | Genentech, Inc. | TENNESSEE RETINA PC | $8 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-03-20 | Genentech, Inc. | TENNESSEE RETINA PC | $1,373 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-03-20 | Genentech, Inc. | TENNESSEE RETINA PC | $1,373 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-03-20 | Genentech, Inc. | TENNESSEE RETINA PC | $1,373 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-03-10 | ANI Pharmaceuticals, Inc. | TENNESSEE RETINA PC | $4,841 | The SYNCHRONICITY Study | 2025 |
| 2025-02-19 | Genentech, Inc. | TENNESSEE RETINA PC | $8,008 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-01-22 | Genentech, Inc. | TENNESSEE RETINA PC | $1,373 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2025-01-08 | Genentech, Inc. | TENNESSEE RETINA PC | $41,605 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2025 |
| 2024-12-12 | Genentech, Inc. | TENNESSEE RETINA PC | $23,818 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-12-11 | Alimera Sciences, Inc. | Tennessee Retina | $1,028 | The SYNCHRONICITY Study | 2024 |
| 2024-12-11 | Alimera Sciences, Inc. | Tennessee Retina | $8,225 | The SYNCHRONICITY Study | 2024 |
| 2024-11-06 | Genentech, Inc. | TENNESSEE RETINA PC | $21 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-10-16 | Genentech, Inc. | TENNESSEE RETINA PC | $82 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-10-10 | Genentech, Inc. | TENNESSEE RETINA PC | $476 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-10-04 | Genentech, Inc. | TENNESSEE RETINA PC | $9,629 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-10-04 | Genentech, Inc. | TENNESSEE RETINA PC | $1,466 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-10-04 | Genentech, Inc. | TENNESSEE RETINA PC | $3,250 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-09-20 | Genentech, Inc. | TENNESSEE RETINA PC | $39,110 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-08-26 | Genentech, Inc. | TENNESSEE RETINA PC | $500 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-08-08 | Alimera Sciences, Inc. | Tennessee Retina | $11,310 | The SYNCHRONICITY Study | 2024 |
| 2024-07-08 | Genentech, Inc. | TENNESSEE RETINA PC | $3,043 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-06-25 | Genentech, Inc. | TENNESSEE RETINA PC | $56,637 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-06-20 | Genentech, Inc. | TENNESSEE RETINA PC | $20,300 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-06-06 | Genentech, Inc. | TENNESSEE RETINA PC | $701 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-05-17 | Alimera Sciences, Inc. | Tennessee Retina | $59,750 | The SYNCHRONICITY Study | 2024 |
| 2024-04-09 | Genentech, Inc. | TENNESSEE RETINA PC | $7,544 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-04-09 | Genentech, Inc. | TENNESSEE RETINA PC | $163 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-03-21 | Genentech, Inc. | TENNESSEE RETINA PC | $10,318 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-03-21 | Genentech, Inc. | TENNESSEE RETINA PC | $3,997 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-03-21 | Genentech, Inc. | TENNESSEE RETINA PC | $5,448 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-03-18 | Genentech, Inc. | TENNESSEE RETINA PC | $4,600 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-03-11 | Genentech, Inc. | TENNESSEE RETINA PC | $2,192 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2024-03-07 | Genentech, Inc. | TENNESSEE RETINA PC | $63,723 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2024 |
| 2023-12-20 | Alimera Sciences, Inc. | Tennessee Retina | $650 | SYNCHRONICITY | 2023 |
| 2023-11-27 | Genentech, Inc. | TENNESSEE RETINA PC | $358 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2023 |
| 2023-09-21 | EyePoint Pharmaceuticals US, Inc. | Tennessee Retina | $92,822 | Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis | 2023 |
| 2023-09-14 | Genentech, Inc. | TENNESSEE RETINA PC | $13,266 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2023 |
| 2023-09-05 | Genentech, Inc. | TENNESSEE RETINA PC | $153 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2023 |
| 2023-07-24 | Genentech, Inc. | TENNESSEE RETINA PC | $22,131 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2023 |
| 2023-07-19 | Genentech, Inc. | TENNESSEE RETINA PC | $2,000 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2023 |
| 2023-06-05 | EyePoint Pharmaceuticals US, Inc. | Tennessee Retina P.C. | $1,114 | A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetoni | 2023 |
| 2023-04-26 | Genentech, Inc. | TENNESSEE RETINA PC | $19,900 | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bowling Green, KY, county Warren County, KY, state Kentucky; placed by its city name.
| Measure | Place (city or town) Bowling Green, KY | County Warren County, KY | State Kentucky |
|---|---|---|---|
| Population B01003 | 75,388 | 140,918 | 4,534,824 |
| Population, 2020 census P1 | 72,294 | 134,554 | 4,505,836 |
| Median age B01002 | 28.7 | 33.3 | 39.1 |
| Under 18 B01001 | 22.7% | 23.7% | 22.6% |
| 65 and over B01001 | 11.4% | 13.2% | 17.3% |
| Households B11001 | 30,633 | 55,643 | 1,814,469 |
| Foreign born B05002 | 15.0% | 10.4% | 4.7% |
| Median household income B19013 | $48,873 | $65,794 | $63,726 |
| Median family income B19113 | $68,257 | $84,378 | $81,505 |
| Per capita income B19301 | $28,971 | $35,497 | $35,821 |
| Poverty rate B17001 | 25.6% | 17.0% | 16.1% |
| Unemployment rate B23025 | 4.9% | 4.4% | 4.9% |
| Civilian labor force B23025 | 38,770 | 73,294 | 2,152,038 |
| Mean commute (minutes) B08013 | 17.8 | 20.3 | 24.0 |
| Bachelor's degree or higher B15003 | 31.2% | 32.3% | 27.6% |
| Housing units B25001 | 33,481 | 59,868 | 2,023,116 |
| Owner-occupied B25003 | 36.6% | 55.6% | 68.3% |
| Renters B25003 | 63.4% | 44.4% | 31.7% |
| Median home value B25077 | $241,900 | $258,000 | $205,600 |
| Median gross rent B25064 | $998 | $1,002 | $967 |
| White, not Hispanic B03002 | 62.1% | 73.8% | 81.5% |
| Black B03002 | 14.1% | 9.1% | 7.6% |
| Hispanic or Latino B03002 | 10.6% | 7.1% | 5.0% |
| Asian B03002 | 7.7% | 5.0% | 1.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.7% in Sep 2026 (4.5% a year earlier); per capita personal income $60,835 in 2025, up 29% in five years (+3.9% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bowling Green, KY.
Comments